CERE News and Press, Ceres Inc. From 11/13/22

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2022 Q3 - Results - Earnings Call Presentation

Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2022 Earnings Conference Call November 08, 2022, 08:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy and Investor Relations Anthony Coles - Chairperson and Chief Executive Officer Ray...

CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences. ...

Cerevel Therapeutics press release ( NASDAQ: CERE ): Q3 GAAP EPS of -$0.66 misses by $0.04 . Cash, cash equivalents and marketable securities as of September 30, 2022, were $1,030 million, inclusive of $238.3 million For further details see: Cerevel Therapeut...

Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with schizophrenia Received FDA Fast Track designation for emraclid...

Summary Neurocrine announced another better-than-expected quarter for Ingrezza, as enhanced sales efforts are driving reacceleration in sales. The company will be announcing Phase II results from multiple programs over the next year, and while these are high-risk programs, success...

BofA Securities has initiated Cerevel Therapeutics ( NASDAQ: CERE ) with a buy rating lauding its platform of novel receptor-selective therapeutic agents for neuropsychiatric indications. The firm has a $39 price target (~52% upside based on Thursday's close) Cerevel's...

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8...

Wells Fargo has initiated Cerevel Theraspeutics Holdings ( NASDAQ: CERE ) with an overweight rating on the potential of its neuroscience pipeline. The firm has a $38 price target (~45% upside based on Friday's close). Analyst Mohit Bansal said while much of the focus o...

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 20 th Annual ...